Shanghai Junshi Biosciences Co., Ltd. (1877.HK)
HKD 16.26
(-0.49%)
HKD 16.26
(-0.49%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 835.26 Million CNY | -9.92% |
| 2022 | 927.21 Million CNY | -66.49% |
| 2021 | 2.76 Billion CNY | 126.34% |
| 2020 | 1.22 Billion CNY | 78.6% |
| 2019 | 684.4 Million CNY | 102509.45% |
| 2018 | 667 Thousand CNY | -4.99% |
| 2017 | 702 Thousand CNY | -74.67% |
| 2016 | 2.77 Million CNY | 0.61% |
| 2015 | 2.75 Million CNY | 30.32% |
| 2014 | 2.11 Million CNY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 302.54 Million CNY | 7.82% |
| 2024 Q1 | 272.71 Million CNY | 24.78% |
| 2023 FY | 835.26 Million CNY | -9.92% |
| 2023 Q1 | 169.64 Million CNY | -87.48% |
| 2023 Q3 | -718.03 Million CNY | -439.42% |
| 2023 Q4 | 218.54 Million CNY | 130.44% |
| 2023 Q2 | 211.54 Million CNY | 24.7% |
| 2022 Q3 | -1.05 Billion CNY | -755.05% |
| 2022 Q1 | 464.84 Million CNY | -41.77% |
| 2022 FY | 927.21 Million CNY | -66.49% |
| 2022 Q4 | 1.35 Billion CNY | 228.65% |
| 2022 Q2 | 160.73 Million CNY | -65.42% |
| 2021 Q3 | 323.68 Million CNY | 4.42% |
| 2021 Q4 | 798.35 Million CNY | 146.65% |
| 2021 Q1 | 1.33 Billion CNY | 220.88% |
| 2021 Q2 | 309.98 Million CNY | -76.77% |
| 2021 FY | 2.76 Billion CNY | 126.34% |
| 2020 Q2 | 329.02 Million CNY | 113.87% |
| 2020 FY | 1.22 Billion CNY | 78.6% |
| 2020 Q4 | 415.92 Million CNY | 30.24% |
| 2020 Q3 | 319.34 Million CNY | -2.94% |
| 2020 Q1 | 153.84 Million CNY | -30.08% |
| 2019 Q1 | 66.34 Million CNY | -61.23% |
| 2019 Q4 | 220.04 Million CNY | 12.47% |
| 2019 Q3 | 195.63 Million CNY | -3.33% |
| 2019 Q2 | 202.38 Million CNY | 205.05% |
| 2019 FY | 684.4 Million CNY | 102509.45% |
| 2018 Q1 | 227 Thousand CNY | 36.13% |
| 2018 Q3 | - CNY | -100.0% |
| 2018 FY | 667 Thousand CNY | -4.99% |
| 2018 Q2 | 166.75 Thousand CNY | -26.54% |
| 2018 Q4 | 171.1 Million CNY | 0.0% |
| 2017 FY | 702 Thousand CNY | -74.67% |
| 2017 Q3 | - CNY | 100.0% |
| 2017 Q4 | 166.75 Thousand CNY | 0.0% |
| 2017 Q2 | -2.9 Million CNY | -522.42% |
| 2017 Q1 | 688.85 Thousand CNY | 123.02% |
| 2016 FY | 2.77 Million CNY | 0.61% |
| 2016 Q1 | -219.81 Thousand CNY | -123.4% |
| 2016 Q4 | 308.87 Thousand CNY | -79.48% |
| 2016 Q3 | 1.5 Million CNY | 784.65% |
| 2016 Q2 | -219.81 Thousand CNY | -0.0% |
| 2015 Q4 | 939.34 Thousand CNY | 0.0% |
| 2015 Q2 | 437.7 Thousand CNY | -0.0% |
| 2015 Q1 | 437.7 Thousand CNY | -57.31% |
| 2015 FY | 2.75 Million CNY | 30.32% |
| 2015 Q3 | 939.34 Thousand CNY | 114.61% |
| 2014 Q3 | 1.02 Million CNY | 3155.25% |
| 2014 FY | 2.11 Million CNY | 0.0% |
| 2014 Q2 | 31.49 Thousand CNY | 0.0% |
| 2014 Q1 | 31.49 Thousand CNY | 0.0% |
| 2014 Q4 | 1.02 Million CNY | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 392.81 Million HKD | -112.633% |
| CK Life Sciences Int'l., (Holdings) Inc. | 947.7 Million HKD | 11.865% |